Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men.
Takeda’s $5.2B Ariad deal pays off with a label expansion in rare form of leukemia
Takeda’s cancer drug Iclusig scored an accelerated approval in combination with chemotherapy from the FDA on Tuesday for newly-diagnosed adults with Philadelphia chromosome-positive acute lymphoblastic